A new study with University of Pittsburgh involvement suggests a novel approach to addiction medicine: integrating it into primary care.
Published in JAMA Network Open in April, researchers found that offering addiction services at doctors’ offices could reduce overdose deaths by a third and extend patients’ life expectancies. The paper was a collaboration of researchers at Boston Medical Center, University of Colorado, University of Pittsburgh School of Medicine, Yale School of Public Health and Washington University in St. Louis.
The team used simulation modeling, based on certain parameters about drug habits and existing statistics. Instead of needing a referral for recovery resources or a prescription to fill at a separate location, this method would equip physicians with tools to prescribe harm reduction services themselves.
The model showed that when doctors provided some addiction services, people lived three years longer and fewer died from drug complications such as overdoses. But some fear that stigma is still too deeply rooted for the model to work in practice.
In Allegheny County, 689 people died of drug overdoses in 2022, about the same as each year prior since 2019, and 90% of those deaths involved opioids. And Black county residents died from drugs by a rate of about two and a half times that of their white counterparts.
Attempting to reduce opioid-related deaths across the country, Congress in late December eliminated the DATA-Waiver (or X-Waiver) program. That required physicians to get special permission to prescribe buprenorphine, a medication that partially activates the brain’s opioid receptors, thus helping to reduce cravings and withdrawal for people with substance use disorders.
Read More
The “DEA fully supports this significant policy reform,” said DEA administrator Anne Milgram in a statement. “Medication ... helps those who are fighting to overcome opioid use disorder by sustaining recovery and preventing overdoses … The elimination of the X-Waiver will increase access to buprenorphine for those in need.”
The researchers sought a model to examine how successful and how cost-effective integrating addiction medicine into primary care could be. The simulation — which accounts for injection infections, hospitalizations, overdoses and deaths, and represents a cohort of 2.25 million people — allowed researchers to follow a population over its entire lifespan.
The study tested three patient outcomes: if a primary care provider referred them to external care (called the “status-quo”); if doctors prescribed buprenorphine only; or if they both prescribed buprenorphine and gave patients a harm reduction kit, including wound care supplies, Narcan and clean needles.
Integrating addiction medicine into primary care in the simulation did increase health care costs by $13,000 per primary care practice over a five-year period, attributed to the cost of training physicians and of supplies such as buprenorphine.
Raagini Jawa, the senior author on the study and a UPMC infectious disease and addiction medicine physician, said the scope of the study was to demonstrate the value of leveraging the existing workforce of physician staff to curb overdose deaths and increase use of resources. Theoretically, doctors’ offices could choose to implement the harm reduction approach outlined in the study.
“Simulations allow us to ask, ‘In a perfect world, what might happen?’” she said. This can reduce costs associated with running a clinical study and also allow researchers to glean information they may not be able to when studying real participants — like what might happen to a given patient 50 years down the line.
“This study adds to the conversation and advocacy really needed in this country,” Jawa said.
Robert Ashford, executive director for Unity Recovery, which provides nonclinical peer support and connects people to recovery resources, said the study is great in theory but would be challenging to implement. The biggest hurdle, in his eyes, is meeting the target population where it is.
Based on his years of experience, he said about 30% of people who use drugs engage in primary care.
“This won’t matter unless we ask, ‘How do we get people who use drugs to seek out primary care?’” he said. “It doesn’t matter where we have services if people can’t access them.”
Jawa, who treats people who use drugs in her practice and at Prevention Point Pittsburgh’s wound care clinic, said many of her patients mention the difficulty of getting into addiction treatment, whereas “often patients have better longitudinal relationships with their PCPs.”
Another hurdle is the existing stigma among doctors themselves.
A 2021 survey of 336 physicians nationwide conducted by public health researchers at Johns Hopkins University found that although 92% of them said people with opioid use disorders could return to productive lives after treatment, only a quarter would be willing to have them as a neighbor. High levels of stigma in the study were associated with an 11% reduction in intention to provide opioid use disorder treatment and a 19% reduction in believing these medications work.
Tools already in doctors’ offices to recognize substance use are not always utilized. SBIRT, which stands for Screening, Brief Intervention and Referral to Treatment, is an approach physicians can use to screen patients for risky substance use behavior. The Substance Abuse and Mental Health Services Administration provides funding to help train staff at colleges, state hospitals and medical residencies on the model.
But there have been reports that SBIRT has seen low uptake, with reasons such as a lack of reimbursement to medical facilities, proper training on substance use disorders and time to viably evaluate patients.
William Johnjulio, chair of the Allegheny Health Network Primary Care Institute, said the study by Jawa and her colleagues makes sense, especially in the context of new guidelines for behavioral health screening.
“The two most effective things we can do as physicians is screen for depression and anxiety and screen for substance use,” he said. When AHN began screening for behavioral health in 2019, they saw an increase in use of services and a decrease in health care costs when patients engaged in those services by $425 a month per member.
“We need to do the next step with opioid use disorder,” Johnjulio said. “I can’t imagine that we’re not going to see the same thing.”
Johnjulio said AHN physicians are on board with medication-assisted treatment and doesn’t see stigma as being a main obstacle — in part because of the presence of AHN’s Center for Inclusion Health, which works directly with people who use drugs.
But that’s not the reality everywhere. Kristin Van Zant, president of the Pennsylvania Society of Addiction Medicine and medical director of NorthEast Treatment Centers in Philadelphia, said she’s seen stigma permeate the medical community.
“Stigma is definitely a barrier to implementation,” she said. “But for younger physicians, I think this is not a hard ask … I think it’s a very hopeful plan to ask PCPs to consider being a provider for this type of treatment,” said Van Zant, who was not involved in the study.
Ashford thinks the study is a step in the right direction but said the best way to tackle such a complex issue is with a multipronged approach.
“The conversation needs to continue, and this is just one element of that,” he said.
Johnjulio agreed: “We need a minimum of three prongs.”
Given that many people who use drugs often end up in emergency rooms and walk-in clinics, focusing resources in those locations might be a more realistic approach, said Ashford, while community members continue to tackle the stigma side of the issue.
“I don’t think there’s a better approach besides attacking this from all fronts,” he said.
Johnjulio said he is already working to implement buprenorphine access in emergency room clinics so if a patient overdoses and is willing to accept treatment, the medication could be started immediately.
“This is an all-hands-on-deck thing,” he said. “You have to be in the streets, in communities and in shelters.”
Another strategy would be to co-localize community outreach services within primary care, as when a certified peer specialist is hired by an emergency department to facilitate addiction resource support. Peer specialists receive training on addiction and often have lived experience. Van Zant and Ashford support this approach.
“I thought this study was an excellent step into conceptualizing how to make a structural difference,” said Van Zant. “The next question is, are primary care providers going to readily adopt this? That’s the barrier.”
Johnjulio called for a central, countywide strategy that incentivizes providers to implement the addiction medicine model and to train staff.
“We are going to need some strong representation from leadership,” said Johnjulio. “Until that happens, I don’t know if we’re going to make a huge impact.”
Jawa felt slightly more optimistic. “There’s 30 years of data that tell us that [providing harm reduction] supplies does not increase risky behavior and actually helps people,” she said. “I’m confident that with advocacy and good research, patients will get better.”
Hanna Webster: hwebster@post-gazette.com, @hannamwebster on Twitter.





Comments
Welcome to Post-Gazette subscriber-only commenting community. Please review our community guidelines.